IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers
Pierfrancesco Marra(King's College London), Andrew Tutt(Institute of Cancer Research), Sonya Hessey(Royal London Hospital), Yin Wu(King's College London), Anita Grigoriadis(London Cancer), Emanuele de Rinaldis(Target (United States)), Fernanda Kyle‐Cezar(King's College London), Johnathan Watkins(King's College London), Adrian Hayday(The Francis Crick Institute), Mamunur Rashid(National Institute of Cardiovascular Diseases), Sumi Mathew(King's College London), Patrycja Gazińska(London Cancer)
Cited by 61
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k